Stefano Andreoli

Dr. Stefano Andreoli

Medical Physics, ASST Papa Giovanni XXIII, Bergamo, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Physica Medica
Verified
Journal Article
Closed access
MPM. Pimpinella
M. Pimpinella
SAStefano Andreoli
Stefano Andreoli
CAC. De Angelis
C. De Angelis
SMS. Della Monaca
S. Della Monaca
MDM. D'ARienzo
M. D'ARienzo
LML. Menegotti
L. Menegotti

3 June 2017 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
STSilvia Takanen
Silvia Takanen
AGA. Gambirasio
A. Gambirasio
GGG. Gritti
G. Gritti
MKM. Källi
M. Källi
SAStefano Andreoli
Stefano Andreoli
LCL. F. Cazzaniga
L. F. Cazzaniga

30 November 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
RLRaffaella Lucchini
Raffaella Lucchini
CFCiro Franzese
Ciro Franzese
SVSuela Vukcaj
Suela Vukcaj
GPGiorgio Purrello
Giorgio Purrello
Denis PanizzaDenis Panizza
Denis Panizza
SASTEFANO ARCANGELI
STEFANO ARCANGELI
Background: The aim of this study was to investigate the feasibility of ultrahypofractionated radiotherapy to the prostate bed in patients with biochemical and/or clinical relapse following radical prostatectomy who were enrolled in the prospective, observational, multicentric POPART trial (NCT04831970). Methods: Patients with post-radical prostatectomy PSA levels of ≥0.1–2.0 ng/mL and/or local relapse at PSMA PET/CT or multiparametric MRI were treated with Linac-based SBRT on the prostate bed up to a total dose of 32.5 Gy in five fractions every other day (EQD21.5 = 74.2 Gy). Maximum acute toxicity was assessed using the Common Terminology Criteria for Adverse Events version 5 scale. International Consultation on Incontinence Questionnaire—Short Form (ICIQ-SF) and Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) scores were assessed at baseline and during the follow-up. Results: From April 2021 to June 2022, thirty men with a median age of 72 years (range 55–82) were enrolled in three centers. The median PSA level before RT was 0.30 ng/mL (range 0.18–1.89 ng/mL). At 3 months post-treatment, no GI or ≥2 GU side effects were reported; three patients (10%) experienced Grade 1 GU toxicity. No changes in ICIQ-SF or in the urinary domains of EPIC-CP were observed, while a transient worsening was registered in the bowel domain. At the same time point, all but two patients, who progressed distantly, were found to be biochemically controlled with a median post-treatment PSA level of 0.07 ng/mL (range 0–0.48 ng/mL). Conclusions: Our preliminary findings show that SBRT can be safely extended to the postoperative setting, without an increase in short-term toxicity or a significant decline in QoL. Long-term results are needed to confirm this strategy.

25 November 2023 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
FFFederica Ferrario
Federica Ferrario
CFCiro Franzese
Ciro Franzese
Valeria FaccendaValeria Faccenda
Valeria Faccenda
SVSuela Vukcaj
Suela Vukcaj
MBMaria Belmonte
Maria Belmonte
SAStefano Arcangeli
Stefano Arcangeli
While SBRT to the prostate has become a valuable option as a radical treatment, limited data support its use in the postoperative setting. Here, we report the updated results of the multicentric Post-Prostatectomy Ablative Radiation Therapy (POPART) trial, investigating possible predictors of toxicities and patient-reported outcomes. Patients with PSA levels between 0.1-2.0 ng/mL after radical prostatectomy received Linac-based SBRT to the prostate bed in five fractions every other day for a total dose of 32.5 Gy (EQD21.5 = 74.3 Gy). Late toxicity was assessed using CTCAE v.5 scale, while EPIC-CP, ICIQ-SF, IIEF 5 questionnaires and PSA levels measured quality of life and biochemical control. Pre- and post-treatment scores were compared using a paired t-test, with MID established at > 0.5 pooled SD from the baseline. A logistic regression analysis was performed to evaluate potential associations between specific patient/tumor/treatment factors and outcome deterioration. From April 2021 to April 2023 a total of 50 pts were enrolled and treated. Median follow-up was 12.2 (3-27) months. No late ≥ G2 GI or GU toxicity was registered. Late G1 urinary and rectal toxicities occurred in 46 % and 4 % of patients, respectively. Among 47 patients completing all EPIC-CP domains, four (9 %) showed worsened QoL, and eleven (26 %) developed erectile dysfunction correlating with PTV D2% (P = 0.032). At Multivariate analysis bladder wall D10cc independently correlated with late G1 GU toxicity (P = 0.034). Median post-treatment PSA nadir was 0.04 ng/mL (0.00 - 0.84). At the last follow-up, six patients presented with biochemical failure, including two nodal relapses. Our findings show that post-prostatectomy SBRT did not result in increased toxicity nor a significant decline in QoL measures, thus showing that it can be safely extended to the postoperative setting. Long-term follow-up and randomized comparisons with different RT schedules are needed to validate this approach.

1 March 2020 in Radiation Physics and Chemistry
Verified
Journal Article
Closed access
GMGabriele Magugliani
Gabriele Magugliani
GLGiulia M. Liosi
Giulia M. Liosi
SAStefano Andreoli
Stefano Andreoli
SCStefano De Crescenzo
Stefano De Crescenzo
EMEros Mossini
Eros Mossini
MMMariani Mario
Mariani Mario

9 March 2015 in Radiation Protection Dosimetry
Verified
Journal Article
Closed access
PDF file
SAStefano Andreoli
Stefano Andreoli
RMRenzo Moretti
Renzo Moretti
FLFerdinando Luca Lorini
Ferdinando Luca Lorini
MLMariavittoria Lagrotta
Mariavittoria Lagrotta
Sometimes, cardiac catheterisation and electrophysiological procedures, diagnostic and interventional, require an anaesthesiological support. The anaesthesiologist receives radiation doses depending on various factors, such as type of procedure and exposure modality, anaesthesiological technique, individual protective devices and operator experience. The aim of this study was to investigate the dose per procedure, the exposure inhomogeneity and the effective dose, E, of a senior anaesthesiologist in the haemodynamic laboratory of Ospedali Riuniti, Bergamo. The dose monitoring was routinely performed with sets of several thermoluminescent dosemeters and an electronic personal dosemeter. The study covered 300 consecutive procedures over 1 y. The anaesthesiologist wore a protective apron, a thyroid collar and glasses (0.5 mm lead-equivalent).